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PATIENT’S SOCIOECONOMIC STATUS AS A PROGNOSTIC FACTOR FOR
ALLOGENEIC STEM CELL TRANSPLANTATION
Silla, L., Fischer, G., Mitto, I., Grossini, M., Bittencourt, H.,
Astigarraga, C., Daudt, L., Bittencourt, R., Paz, A. Hospital de Clınicas
de Porto Alegre, Porto Alegre, RS, Brazil.
Patient’s age, stage of underlying disease, graft-versus-host dis-
ease, infections, and number of cells infused are among the multiple
variables that affect outcome of Allogeneic Stem-cell Transplanta-
tion (Allo-SCT). However, impact of socioeconomic status (SeS) is
still to be defined. The aim of the present study was to assess the SeS
influence on the outcome of allo-SCT. Two hundred and four
patients submitted to HLA-identical related Allo-SCT were retro-
spectively studied. Median age was 33 years. One hundred sixty-six
patients had malignancies (CML 68, ALL/AML 63, MDS 12,
others 23), and one hundred and forty-one patients were CMV pos-
itive. Graft-versus-Host Disease (GVHD) prophylaxis was cyclo-
sporine 1 methotrexate in 147 patients. Socioeconomic status (A
to E, being A the highest and E the lowest level) was adapted
from the Brazilian Association of Market Research Agencies classifica-
tion. Sixty-six, eighty three and fifty-five patients were classified as
A1B (higher SeS), C (intermediate), and D1E (lower SeS) socio-
economic status, respectively. Median time to neutrophil and plate-
let engraftment was 19 and 18 days, respectively. Cumulative
incidence of aGVHD grade 2–4 and cGVHD were 28.5% and
28.4% respectively. Transplant-related mortality (TRM at day
100) was 22.5%. Variables influencing TRM on univariate analysis
were: SeS, use of BuCy and use of TBI. To belong to D1E SeS was
associated with a higher TRM in multivariate analysis (HR5 2.96;
P 5 0.009). Estimated overall survival (OS) at 5 years was 52.4%.
On univariated analysis, SeS, age, CMV serology status, and a low
risk for relapse influenced OS. A D1E SeS (HR 5 4.34; P \
0.001) was associated with a worst outcome on multivariate analysis.
In conclusion, a lower socioeconomic status is a strong prognostic
factor in patients undergoing allo-SCT in Brazil, influencing
TRM and overall survival.296
SIMULTANEOUS HAPLOIDENTICALLY MISMATCHED STEM CELL TRANS-
PLANTATION FROM MULTI-DONORS (MDT) IN HUMANS OFFERS BET-
TER ENGRAFTMENT AS COMPARED TO SINGLE HAPLOIDENTICAL
DONOR
Shapira, M.Y., Resnick, I.B., Gesundeheidt, B., Samuel, S., Drey, L.,
Verkholevsky, Y., Slavin, S., Or, R. Hadassah University Hospital, Jer-
usalem, Israel.
Introduction: : For patients with no matched sibling available for
allogeneic SCT (approximately 70% of patients) an alternative op-
tion is SCT from a relative carrying only one identical HLA haplo-
type (haplo-SCT), which may provide a donor for almost every
patient at optimal timing. We hypothesized that simultaneous
transplantation from 2 donors may improve the engraftment fol-
lowing haplo-SCT. Patients and Methods: : Fifteen ultra high-
risk patients (median age 20 y, 9–52, mostly after 1–2 previous
SCTs and 13 of them with refractory disease) were included. Con-
ditioning regimen was fludarabine based. All grafts were T cell de-
pleted. Results: : All 14 evaluable patients engrafted but one of
them later rejected the graft. The time for neutrophil engraftment
(0.5 & 1.0  109/L) was fast, 11 d (9–24) and 12 d (10–28) respec-
tively. Platelets engrafted even earlier (20 & 100  109/L), 10
d (8–45) and 14 d (12–32) respectively. Three patients demonstrate
continuous bi-donor hematopoiesis (follow up 72, 128 and 168 d)
while 11 patients converted to single donor hematopoiesis within
a median of 21 d (14–39). Comparison of MDT patients to an ear-
lier patient group receiving a similar protocol with a single donor
(SDT) showed better granulocyte and platelet engraftment (p \
0.001 for both). Additionally, no primary graft failure occurred in
patients undergoing MDT, while in SDT it occurred in 9/38 pa-
tients (p \ 0.001). One patient in-which leukemia persisted
throughout the conditioning, leukemic cells disappeared upon the
conversion to single donor chimerism. Despite major blood type
differences, no hemolysis related side-effects were noted. Eight pa-tients developed GVHD (mostly grade 1/2). Conclusion: : MDT is
safe and induces fast and durable engraftment of both myeloid and
thrombocyte lineages in patients undergoing haplo-SCT. Further
studies should follow this report.297
SALVAGE TRANSPLANTATION FOR ALLOGRAFT FAILURE UTILIZING
FLUDARABINE AND ALEMTUZUMAB AS THE CONDITIONING REGIMEN
Bolan˜os-Meade, J., Luznik, L., Jones, R.J., Fuchs, E.J. The Sidney Kim-
mel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Graft failure remains a cause for elevated morbidity and mortality
after myeloablative allogeneic stem cell transplantation. This report
includes the outcome of nine patients that received a salvage alloge-
neic stem cell transplant after failing (rejecting) one (n5 8) or two (n
5 1) previous transplants. Three were males and the median age was
48.5. Diagnoses included: CMML 2, AML 2, CML 1, CLL 1, HL
1, NHL 1 and MDS 1. Median time between failed and salvage
transplant was 62 days (range 43–84). Patients received fludarabine
30 mg/m2 IV and alemtuzumab 20 mg IV every day from day -6 to
day -2. On day -2 they started cyclosporine 5 mg/kg IV over 6 hours
every day (n 5 8) or tacrolimus 1 mg PO every 12 hours (keeping
levels 5–15 ng/mL after 72 hours)(n 5 1). Day 0 was the infusion
of donor stem cells. By day 13, cyclosporine was decreased to 2.5
mg/kg IV and eventually switched to oral form once tolerated. Pa-
tients received G-CSF support until neutrophil recovery. Grafts
consisted of allogeneic HLA identical PBSC from a sibling in 6
cases, MUD PBSC in 2 and MUD BM in 1. All the patients received
the grafts from the same donor as in their previous transplant except
1. All patients engrafted. Neutrophil recovery was seen at a median
of 12 days. Seven patients achieved 100% chimerism by restriction
length fragment polymorphism by day 60, 1 by day 30, and 1 died
before chimerism evaluation but with neutrophil recovery. The
therapy was well tolerated with low toxicity. There are so far only
two cases of GVHD; one patient had skin only (acute grade II),
and the second had acute of the skin (grade II) and later chronic
of the skin (mild chronic/limited). With a median overall survival
of 191 days (range 37–738), six patients are alive and in complete re-
mission, three patients have died: two of relapse and one of a fungal
infection in the setting of GVHD therapy. The combination of flu-
darabine and alemtuzumab appears to be an effective and well toler-
ated conditioning regimen for reconditioning patients suffering
from graft failure.298
HIGHER CD 34 CELL DOSES REDUCE NON RELAPSE MORTALITY (NRM)
AND DO NOT INCREASE THE INCIDENCE OF GRAFT VERSUS HOST DIS-
EASE (GVHD) FOLLOWING UNRELATED DONOR BLOOD STEM CELL
TRANSPLANTATION (SCT)
Narayanan, S., Barnett, M.J., Abou Mourad, Y.R., Forrest, D.L.,
Hogge, D.E., Lavoie, J.C., Nantel, S.H., Shepherd, J.D., Song, K.W.,
Sutherland, H.J., Toze, C.L., Smith, C.A., Power, M., Nevill, T.J.
BC Cancer Agency and University of British Columbia, Vancouver,
BC, Canada.
Background: : Higher CD34 cell doses have been shown to in-
crease the incidence of acute (Przepiorka D et al, 1999) and exten-
sive chronic GVHD (Zaucha et al, 2001) following HLA-matched
sibling SCT. Less is known about the influence of CD 34 cell
dose in the unrelated SCT setting.Methods:A retrospective review
was performed involving 81 consecutive adult patients (pts) who un-
derwent unrelated donor G-CSF mobilised blood SCT in Vancou-
ver between June 2000 and October 2006. NRM, relapse risk (RR)
and overall survival (OAS) estimates were determined using a Ka-
plan-Meier technique and univariate and multivariate analyses
were done to identify factors predictive of GVHD and outcome,
with particular focus on cell dose administered. Characteristics:
There were 46 male and 35 female pts with a median age of 44
(range 17–58) years. Diagnoses included acute leukemia (39 pts),
chronic leukemia (14 pts), lymphoma (15 pts) and other (13 pts).
Poster Session II 111Conditioning was TBI-based in 80/81 pts and GVHD prophylaxis
was with Cyclosporine and short-course Methotrexate (MTX) (15
mg/m2 d 1 1 and 10 mg/m2 d 1 3, d 1 6 and d 1 11). Fifty of
81 pts received.80% of the planned MTX dose. Forty three pts re-
ceived SCT from a 10/10 high-resolution HLA-matched donor, 25
pts received a 1-antigen mismatched SCT, 12 pts received a 2-anti-
gen mismatched SCT and 1 pt a 3-antigen mismatched SCT. The
donor was male for 68 pts and female for 13 pts. Median CD 34 cell
dose was 7.75  106 (range-9.46  104–33.6  106)/kg. Results:
The estimated 3-year NRM, RR and OAS were 39% (95%CI
25%-50%), 30% (95%CI 17%-41%) and 43% (95%CI 31%-
58%), respectively. In multivariate analysis, CD 34 cell dose
.7.75  106/kg was associated with faster neutrophil engraftment,
p\0.001 and reduced NRM (28% vs. 49%, p5 .019), but did not
influence the incidence of either acute or chronic GVHD or OAS.
On multivariate analysis the most important predictor of reduced
grade 3–4 acute GVHD (22% vs. 49%, p 5 .005), NRM (30 vs.
65%, p5 .006), and improved OAS (50% vs. 24%%) was adminis-
tration of .80% of the planned MTX dose. Conclusion: A higher
CD34 cell dose in unrelated donor SCT does not adversely influ-
ence the incidence of GVHD and is associated with faster neutro-
phil engraftment and a reduction in NRM. Delivery of at least
80% of the planned short-course MTX GVHD prophylaxis con-
tinues to be critical in producing a favourable outcome.299
THE RELATION BETWEEN THE FREQUENCY OF PRESENCE OF THROM-
BOPHILIA AND THROMBOEMBOLIC COMPLICATIONS AFTER ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)
Topcuoglu, P., Gunaltay, S., Dalva, K., Bilgin, A.U., Arat, M.,
Ozcan, M. Ankara University, Ankara, Turkey.
Venous thromboembolism (TE) occurs as a consequence of ge-
netic and environmental factors. Important genetic risk factors are
deficiencies of natural anticoagulants, antithrombin-III (AT-III),
protein C (PC) and PS, and genetic mutations of factor V leiden
(FVL) and prothrombin (PTH A20210). Thrombotic complica-
tions after HCT are usually catheter-related thrombosis (CRT),
pulmonary TE (PTE) and deep vein thrombosis (DVT). Our aim
in this study was to evaluate the effects of the deficiencies of ATIII,
PC and PS, and the gene mutations of FVL and PTH on the inci-
dence of the development of TE complications and liver sinusoidal
obstruction syndrome (SOS) at the early or late period post-HCT.
In our center, pre-transplant work-up includes routine thrombo-
philia tests. Between Apr 1999-Jan 2007 260 patients (M/F: 145/
115, median age: 34 years) admitted to our transplantation center
were retrospectively analyzed for the relation of the presence of
thrombophilia and the frequencies of the occurrence of a TE com-
plications and liver SOS. All but 6 patients (n5 254) underwent al-
logeneic HCT from an HLA identical sibling donor. The ratios of
the detection of the plasma activation level below 50% for PC, PS
and AT-III were 5.8% (12/206), 15.7% (32/204) and 25.4% (66/
260), respectively. Gene mutations were studied in 198 patients
prior to transplant and the frequencies of gene mutations were de-
tected in 11.6% patients (n5 23) either FVL (n5 14) or PTH (n5
9) gene. None of the patients had both mutations, FVL and PTH.
At the peri- or post-transplantation period we observed venous TE
in 24 patients (17 CRT, 2 PE and 5 DVT), liver SOS in 23 patients
and myocard infarction at the early period in only one patient. In 4
out of 12 patients with low PC activity CRT occurred, and liver
SOS was observed in only one patient. In 6 out of 24 patients
with genetic mutation developed a TE complication, 5 CRT and
1 PTE. CRT occurred in 4 of 14 patients with FVL mutation, while
1 CRT and 1 PTE among 9 patients with PTH mutation were ob-
served. Liver SOS was seen in only one patient with PTH heterozy-
gote positive. We found the presence of low PC level or genetic
mutation increased the frequency of the development of TE (OR:
6.9 and 3.7, respectively), but no effect on the liver SOS. In conclu-
sion, the use of thromboprophylaxis at peri-transplant period in pa-
tients with genetic mutations is still a controversial topic; which
should be elucidated with controlled studies.300
ONCE DAILY BUSULFAN CYCLOPHOSPHAMIDE IS WELL TOLERATED
AND EFFECTIVE PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
LeMaistre, J., Bachier, C., Smith, B., LeMaistre, C.F., Shaughnessy, P.J.
Texas Transplant Institute, San Antonio, TX.
Intravenous busulfan (Bu) allowes for the delivery of Bu in one
dose instead of dividing 4 times per day. Pharmacokinetic (PK)
studies of Bu support the feasibility of once daily dosing, and prior
clinical studies found no unexpected toxicity of once daily Bu when
combined with fludarabine. Based on this data we began an institu-
tional protocol of delivering Bu once daily follwed by standard cy-
clophosphamide (CY) and allogeneic hematopoietic stem cell
transplantation (HCT). We report a retrospective review of our in-
stitutional data using once daily BuCY vs 4 daily BuCY and total
body irradiation (TBI)/CY in pts who received allogeneic HCT
from January 2000 to December 2006. Bu 3.2 mg/kg daily  4
days followed by CY 60 mg/kg daily  2 days was given to 42 pa-
tients (pts). Bu 0.8 mg/kg given 4 daily for 4 days followed by
CY 60 mg/kg was given to 15 pts. CY 60 mg/kg daily for 2 days
and fractionated TBI 1200 cGy delivered over 3 days was given to
60 pts. All donors were HLA matched at A, B, C, DR, and DQ
and were related/unrelated in 23/19, 11/4, and 21/39 in the once
daily BuCY, 4 daily BuCY, and TBI/CY, respectively. Signifi-
cantly more pts with myeloid leukemias received a BuCY regimen
and significantly more pts with lymphoid malignancies received
TBI/CY. Median follow up for all pts was 370 days. VOD devel-
oped in 2 pts in the once daily BuCY group, 1 pt in the 4 daily
BuCY group, and in no pts in the TBI/CY group. Acute GVHD
grade II-IV occured in 33% of the once daily BuCY pts, 53% of
the 4 daily BuCY pts, and 32% of the TBI/CY pts. Estimated ac-
tuarial transplant related mortality (TRM) and survival are de-
scribed in the table below. There was no statistical difference in
TRM or survival between the once daily and 4 daily BuCY groups
or the total BuCY group and TBI/CY group. The once daily BuCY
group had significantly less TRM than the TBI/CY group at 100
days (p5 0.04) and at 1 year (p5 0.01). The once daily BuCY group
also had significantly better survival at one year compared to the
TBI/CY group (p 5 0.01), but this became non-significant at 3
years. The significant differences in the pt populations treated in
the BuCY and TBI/CY groups, as well as the retrospective nature
of this study, limit the ability to draw conclusions comparing the
groups. However, this review does demonstrate once daily BuCY
and allogeneic HCT is well tolerated with no unexpected TRM,
and provides good long term survival in pts with myeloid malignan-
cies.Survival and TRM
1  BuCY 4  BuCY CY/TBI
(95%CI) (95%CI) (95%CI)100 day TRM 7% (1–16) 21% (7–51) 22% (15–35)
1 year TRM 21% (11–38) 37% (17–69) 45% (33–59)
1 year Survival 70% (53–82) 47% (21–69) 49% (35–61)
3 year Survival 43% (24–59) 27% (8–50) 37% (24–49)301
THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR)
BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (AHCT) OUTCOME
Serbest, E., Topcuoglu, P., Dalva, K., Bilgin, A.U., Soydan, E.A.,
Ozcan, M., Arslan, O., Ilhan, O., Beksac, M., Gurman, G., Arat, M.
Ankara University, Ankara, Turkey.
STR marker systems are used in the monitoring of hematopoietic
chimerism in patients after AHCST. The biological effect of STR
disparity on AHCT outcome has rarely been studied. Therefore,
we aimed to evaluate the impact of STR disparity on allo-HCT out-
come in our single center. Between Sept 2001 and Feb 2007, 150 pa-
tients (81M/69F, median age: 34 ys) underwent AHCT (Stem cell
